We are live on ! Find out more
TPST icon

Tempest Therapeutics
TPST

35 hedge funds and large institutions have $5.89M invested in Tempest Therapeutics in 2018 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 8

6% more funds holding

Funds holding: 33 → 35 (+2)

12% less capital invested

Capital invested by funds: $6.68M → $5.89M (-$791K)

50% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 6

Holders
35
Holders Change
+2
Holders Change %
+6.06%
% of All Funds
0.8%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
3
Reduced
6
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PM
Prosight Management
Texas
+$1.26M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$933K
3
AIC
AWM Investment Company
New York
+$248K
4
Renaissance Technologies
Renaissance Technologies
New York
+$123K
5
WVP
Worth Venture Partners
New Jersey
+$86.5K

Top Sellers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$1.16M
2
SM
Sabby Management
Florida
-$574K
3
BCM
Bridgeway Capital Management
Texas
-$207K
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$112K
5
ERSOT
Employees Retirement System of Texas
Texas
-$81K
Name Holding Trade Value Shares
Change 		Change in
Stake
PM
1
Prosight Management
Texas
$1.12M +$1.26M +523 New
Vanguard Group
2
Vanguard Group
Pennsylvania
$980K +$24K +10 +2%
Renaissance Technologies
3
Renaissance Technologies
New York
$883K +$123K +51 +14%
Point72 Asset Management
4
Point72 Asset Management
Connecticut
$828K +$933K +388 New
GC
5
GMT Capital
Georgia
$585K – – –
BlackRock
6
BlackRock
New York
$278K – – –
AIC
7
AWM Investment Company
New York
$219K +$248K +103 New
SM
8
Sabby Management
Florida
$187K -$574K -239 -73%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$156K – – –
Jacobs Levy Equity Management
10
Jacobs Levy Equity Management
New Jersey
$140K – – –
BCM
11
Bridgeway Capital Management
Texas
$109K -$207K -86 -63%
WVP
12
Worth Venture Partners
New Jersey
$77K +$86.5K +36 New
Northern Trust
13
Northern Trust
Illinois
$49K – – –
HCM
14
Howland Capital Management
Massachusetts
$46K – – –
Wells Fargo
15
Wells Fargo
California
$40K +$9.61K +4 +27%
California Public Employees Retirement System
16
California Public Employees Retirement System
California
$35K – – –
OC
17
Oppenheimer & Co
New York
$26K – – –
Two Sigma Investments
18
Two Sigma Investments
New York
$25K -$28.8K -12 -50%
Bank of New York Mellon
19
Bank of New York Mellon
New York
$23K – – –
Two Sigma Advisers
20
Two Sigma Advisers
New York
$18K – – –
State Street
21
State Street
Massachusetts
$14K -$2.4K -1 -14%
PL
22
PWMCO LLC
Illinois
$12K – – –
PAM
23
Panagora Asset Management
Massachusetts
$7K -$21.6K -9 -75%
Deutsche Bank
24
Deutsche Bank
Germany
$7K – – –
TAM
25
Tiverton Asset Management
Delaware
$6K +$7.21K +3 New
1
2

TPST Hedge Fund Activity: Q3 2018 in Review

35 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q3 2018, worth a combined $5.89M — down 12% from $6.68M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new TPST positions and 8 closed out — a net gain of 2 holders — while 3 added to existing stakes and 6 trimmed.

The largest buyer was Prosight Management, opening a new position worth an estimated $1.26M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $1.16M sold.

  • 35 institutional investors held Tempest Therapeutics (TPST) as of Q3 2018, up from 33 in Q2 2018.
  • Funds reported $5.89M of Tempest Therapeutics stock for Q3 2018, down 12% quarter-over-quarter.
  • 10 funds opened new Tempest Therapeutics positions in Q3 2018 and 8 closed out, a net change of +2 holders.
  • The largest Tempest Therapeutics buyer in Q3 2018 was Prosight Management, an estimated $1.26M added.
  • The largest Tempest Therapeutics seller in Q3 2018 was Adage Capital Partners, an estimated $1.16M sold.

Based on aggregated 13F filings for Q3 2018.